Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.54 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.54 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30516614 | 0.86 | CYP2E1 (0.55) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL370074 | 0.86 | CYP2E1 (0.55) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL30516607 | 0.84 | CYP2E1 (0.57) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL368446 | 0.84 | CYP2C9 (0.54) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL6872027 | 0.84 | CYP2E1 (0.57) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL30516592 | 0.84 | CYP19A1 (0.51) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL2112340 | 0.84 | RAB9A (0.74) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL13363888 | 0.84 | CYP19A1 (0.51) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL4805 | 0.83 | RAB9A (0.69) | CYP2C9CYP2C19SMN1; SMN2RAB9ATP53 | |
| SCHEMBL23930594 | 0.82 | RAB9A (0.50) | CYP2C19SMN1; SMN2RAB9AUSP30NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697979-B | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4139287-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| EP-4139287-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115697979-A | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021214020-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | CYP2A6 3468/4885CYP2C9 3298/4885CYP2C19 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.